PL2167039T3 - Ulepszone preparaty depot - Google Patents

Ulepszone preparaty depot

Info

Publication number
PL2167039T3
PL2167039T3 PL08767765T PL08767765T PL2167039T3 PL 2167039 T3 PL2167039 T3 PL 2167039T3 PL 08767765 T PL08767765 T PL 08767765T PL 08767765 T PL08767765 T PL 08767765T PL 2167039 T3 PL2167039 T3 PL 2167039T3
Authority
PL
Poland
Prior art keywords
depot formulations
improved depot
improved
formulations
depot
Prior art date
Application number
PL08767765T
Other languages
English (en)
Inventor
Jeremy C. Wright
Felix Theeuwes
John W. Gibson
Keith E. Branham
Stefania Sjobeck
Original Assignee
Durect Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durect Corporation filed Critical Durect Corporation
Publication of PL2167039T3 publication Critical patent/PL2167039T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)
PL08767765T 2007-05-18 2008-05-16 Ulepszone preparaty depot PL2167039T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93073907P 2007-05-18 2007-05-18

Publications (1)

Publication Number Publication Date
PL2167039T3 true PL2167039T3 (pl) 2017-03-31

Family

ID=39708928

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08767765T PL2167039T3 (pl) 2007-05-18 2008-05-16 Ulepszone preparaty depot

Country Status (12)

Country Link
US (8) US20080287464A1 (pl)
EP (2) EP3115038A1 (pl)
JP (4) JP5599705B2 (pl)
CN (2) CN101677952B (pl)
AU (1) AU2008254538B2 (pl)
CA (1) CA2686137C (pl)
DK (1) DK2167039T3 (pl)
ES (1) ES2606951T3 (pl)
HU (1) HUE030789T2 (pl)
IL (1) IL202181A (pl)
PL (1) PL2167039T3 (pl)
WO (1) WO2008143992A2 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CN101678125A (zh) * 2007-04-03 2010-03-24 特里梅里斯公司 用于递送抗病毒肽治疗剂的新制剂
HUE030789T2 (en) 2007-05-18 2017-06-28 Durect Corp Improved depot formulation
CN101801415B (zh) 2007-05-25 2015-09-23 Rb医药品有限公司 利培酮化合物的持续递送制剂
US8524267B2 (en) 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
PT2394663T (pt) 2010-05-31 2021-11-26 Farm Rovi Lab Sa Composições para implantes biodegradáveis injectáveis
ES2589106T3 (es) * 2010-05-31 2016-11-10 Laboratorios Farmaceuticos Rovi, S.A. Composición inyectable antipsicótica de liberación controlada
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
EP2643009A4 (en) * 2010-11-24 2015-04-01 Durect Corp BIODEGRADABLE DRUG DELIVERY COMPOSITION
SI2529756T1 (sl) * 2011-05-31 2021-09-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija vsadka z risperidonom in/ali paliperidonom
AU2012321101A1 (en) 2011-11-23 2013-06-06 Durect Corporation Radiation-sterilized biodegradable drug delivery compositions
BR112015022023B1 (pt) * 2013-03-11 2022-12-06 Durect Corporation Composição de liberação controlada injetável compreendendo transportador líquido de alta viscosidade
US20140308352A1 (en) * 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
EP3079668A1 (en) 2013-12-09 2016-10-19 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
ES2969514T3 (es) 2015-03-18 2024-05-21 Santen Pharmaceutical Co Ltd Composición farmacéutica de liberación sostenida
AU2017290143A1 (en) 2016-06-30 2019-02-21 Durect Corporation Depot formulations
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
CA3146064A1 (en) * 2019-07-18 2021-01-21 Durect Corporation Long-acting formulations and vehicles
WO2021011891A1 (en) * 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
JP2023515918A (ja) 2020-01-13 2023-04-17 デュレクト コーポレーション 不純物が低減された徐放性薬物送達システム及び関連の方法
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4622219A (en) 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4891225A (en) 1984-05-21 1990-01-02 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
IT1198449B (it) 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5149543A (en) 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
DE69429820T3 (de) 1993-11-19 2013-02-28 Alkermes Controlled Therapeutics, Inc. Herstellung biologisch abbaubarer, einen biologisch aktiven stoff enthaltender, mikropartikel
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
DK0904063T3 (da) 1996-05-07 2002-12-16 Alkermes Inc Fremgangsmåde til fremstilling af mikropartikler
WO1998027962A2 (en) * 1996-12-20 1998-07-02 Alza Corporation Injectable depot gel composition and method of preparing the composition
US6733767B2 (en) * 1998-03-19 2004-05-11 Merck & Co., Inc. Liquid polymeric compositions for controlled release of bioactive substances
US7208011B2 (en) * 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
JP2004511431A (ja) 2000-06-28 2004-04-15 アトゥル・ジェイ・シュクラ 生物活性物質を含む生分解性ビヒクルおよび送達システム
CA2429898C (en) * 2000-11-16 2011-02-22 Durect Corporation Devices and methods for cholesterol management
US20040018238A1 (en) * 2001-02-26 2004-01-29 Shukla Atul J Biodegradable vehicles and delivery systems of biolgically active substances
CA2440387A1 (en) * 2001-03-23 2002-10-03 Durect Corporation Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
GB0112324D0 (en) * 2001-05-21 2001-07-11 Croda Int Plc Compounds
ATE507816T1 (de) 2001-11-14 2011-05-15 Durect Corp Injizierbare depotzusammensetzungen und deren verwendung
EP1446099B1 (en) 2001-11-14 2009-07-15 Durect Corporation Injectable depot composition
MXPA04004665A (es) 2001-11-14 2004-09-10 Alza Corp Composiciones de deposito inyectable y uso de los mismos.
US20040258731A1 (en) 2001-11-21 2004-12-23 Tsuyoshi Shimoboji Preparation approriate for cartilage tissue formation
TWI314464B (en) 2002-06-24 2009-09-11 Alza Corp Reusable, spring driven autoinjector
US20040109893A1 (en) * 2002-06-25 2004-06-10 Guohua Chen Sustained release dosage forms of anesthetics for pain management
AR039729A1 (es) 2002-06-25 2005-03-09 Alza Corp Formulaciones de deposito de corta duracion
ES2321505T3 (es) 2002-07-31 2009-06-08 Alza Corporation Composiciones de deposito de polimero multimodal inyectables y empleo de las mismas.
AU2003257994A1 (en) 2002-07-31 2004-02-16 Alza Corporation Injection device providing automatic needle retraction
JP2006508127A (ja) 2002-11-06 2006-03-09 アルザ・コーポレーション 制御された放出性デポー剤配合物
ES2350689T3 (es) 2002-12-13 2011-01-26 Durect Corporation Sistema de suministro de fármacos oral que comprende materiales vehículo líquidos de alta viscosidad.
DE10312346A1 (de) * 2003-03-20 2004-09-30 Bayer Healthcare Ag Kontrolliertes Freisetzungssystem
JP2007504256A (ja) 2003-09-01 2007-03-01 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド 生物活性剤の送達のための組成物及び方法
US20050281879A1 (en) 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US20100016267A1 (en) * 2004-03-15 2010-01-21 Felix Theeuwes Pharmaceutical compositions for administraton to a sinus
US20050240166A1 (en) * 2004-04-26 2005-10-27 Microsolutions, Inc. Implantable device, formulation and method for anti-psychotic therapy using risperidone
US8852638B2 (en) * 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
DK1984009T3 (da) 2006-01-18 2013-01-28 Qps Llc Farmaceutiske sammensætninger med forbedret stabilitet
HUE030789T2 (en) * 2007-05-18 2017-06-28 Durect Corp Improved depot formulation
EP2244679A4 (en) 2008-02-08 2013-10-09 Qps Llc NON-POLYMERIC COMPOSITIONS FOR CONTROLLED MEDICINAL PRODUCTION
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material

Also Published As

Publication number Publication date
DK2167039T3 (en) 2017-01-09
US20190030032A1 (en) 2019-01-31
WO2008143992A2 (en) 2008-11-27
JP6339640B2 (ja) 2018-06-06
US20230146925A1 (en) 2023-05-11
US10028957B2 (en) 2018-07-24
CA2686137A1 (en) 2008-11-27
JP2018158921A (ja) 2018-10-11
JP6018603B2 (ja) 2016-11-02
JP2010527926A (ja) 2010-08-19
US20210121467A1 (en) 2021-04-29
IL202181A (en) 2014-11-30
EP3115038A1 (en) 2017-01-11
JP5599705B2 (ja) 2014-10-01
JP2014193880A (ja) 2014-10-09
ES2606951T3 (es) 2017-03-28
US20200101073A1 (en) 2020-04-02
AU2008254538A1 (en) 2008-11-27
CN101677952A (zh) 2010-03-24
IL202181A0 (en) 2010-06-16
WO2008143992A3 (en) 2009-09-24
CN101677952B (zh) 2012-12-05
AU2008254538B2 (en) 2013-11-07
US20080287464A1 (en) 2008-11-20
HUE030789T2 (en) 2017-06-28
US20130289053A1 (en) 2013-10-31
US20160045601A1 (en) 2016-02-18
CA2686137C (en) 2021-01-12
CN103007288B (zh) 2015-02-11
EP2167039B1 (en) 2016-09-28
EP2167039A2 (en) 2010-03-31
JP2017014241A (ja) 2017-01-19
CN103007288A (zh) 2013-04-03
US20160279131A1 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
IL202181A0 (en) Improved depot formulations
GB0711656D0 (en) Formulations
GB0716385D0 (en) Formulations
EP2219637A4 (en) AVENANTHRAMIDE COMPOSITIONS
IL199656A0 (en) Tablet-in-tablet compositions
HUE059171T2 (hu) Kompozíciók
GB0724342D0 (en) Anitbacterial compositions
GB0700534D0 (en) Composition
GB0711683D0 (en) Compositions
GB0712884D0 (en) Formulations
GB0712024D0 (en) Compositions
GB0711957D0 (en) Formulations
GB0809979D0 (en) Formulations
GB0715068D0 (en) Improved composition
GB0810232D0 (en) Formulations
GB0706343D0 (en) Composition
GB0705885D0 (en) Composition
GB0702446D0 (en) Composition
GB0703719D0 (en) Composition
GB0706739D0 (en) Composition
GB0704651D0 (en) Composition
GB0705179D0 (en) Formulations
EP2214697A4 (en) COMPOSITIONS OF NELL-1
GB0704659D0 (en) Composition
GB0713886D0 (en) Formulations